The US government has filed a lawsuit against Regeneron, claiming that the company falsely inflated the average sales price for ophthalmology blockbuster Eylea to manipula
Novartis has confirmed it will discontinue development of a gene therapy for sight-robbing disease geographic atrophy (GA) two years after acquiring its UK-based developer
Shares in Outlook Therapeutics cratered today after the FDA rejected the company's marketing application for its lead drug ONS-5010, a therapy for age-related macular dege
Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector,<
Endeavor BioMedicines has completed a third round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.